Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

DeCODE Discovers Second Common Genetic Risk Factor For Atrial Fibrillation And Stroke
Scientists at deCODE genetics (Nasdaq: DCGN) and colleagues from Europe and the United States today report the discovery of a common single-letter variant in the sequence of the human genome (SNP) conferring increased risk of atrial fibrillation (AF) and stroke. The findings will be integrated directly into the deCODE AF(TM) reference laboratory test for gauging individual risk of AF and stroke and helping to identify stroke patients who may benefit from enhanced monitoring for AF.
generic viagra online
ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin At ASCO
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced that it presented final data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd.
News of the day
ANA Reaffirms Support Of Health Reform Legislation
The American Nurses Association (ANA) reached out to lawmakers Friday, with a letter in support of H.R. 3200 "America"s Affordable Health Choices Act of 2009." After a contingent from ANA took part in a Rose Garden press conference with President Obama July 15th, ANA set out to engage lawmakers, nurses, and other health professionals across the country to voice their commitment to real healthcare reform.
Mental Health

Teva Announces Approval And Launch Of Generic Urso 250(R) And Urso Forte(R)

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that the U.S. Food and Drug Administration has granted approval for the Company"s Abbreviated New Drug Application (ANDA) for Ursodiol Tablets USP, 250 mg and 500 mg. Teva"s Ursodiol Tablets are the AB-rated generic equivalents of Axcan"s Urso 250® and Urso Forte®, which are indicated for treatment of patients with primary biliary cirrhosis. Shipment of this product has commenced. The brand product had annual sales of approximately $76 million in the United States for the twelve months that ended March 31, 2009, based on IMS sales data. Teva Pharmaceutical Industries Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009